Our proposed molecular signature that is composed of 39 NAMPT-mediated genes is a promising prognostic marker, because N39 was solely developed based on the discovery cohort and its prognostic power was validated in two independent validation cohorts for lung and breast cancer, respectively. The gene discussed is NAMPT; the disease is breast carcinoma.